|Bid||17.50 x 1000|
|Ask||17.75 x 1100|
|Day's Range||17.13 - 19.14|
|52 Week Range||14.48 - 31.35|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.22|
TBPH earnings call for the period ending December 31, 2020.
Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.37% over the past year to ($0.92), which beat the estimate of ($1.02). Revenue of $18,730,000 declined by 36.51% from the same period last year, which missed the estimate of $20,850,000. Outlook Theravance Biopharma Sees Operating Expenses For R&D At $195M-$225M How To Listen To The Conference Call Date: Feb 23, 2021 Time: 05:00 PM View more earnings on TBPH ET Webcast URL: https://edge.media-server.com/mmc/p/8r4422vu Technicals Company's 52-week high was at $31.35 Company's 52-week low was at $14.48 Price action over last quarter: Up 5.12% Company Overview Theravance Biopharma is a diversified biotechnology company that creates medicines to treat serious illnesses. The company's research and development are concentrated primarily on four therapeutic areas-infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease. Its commercial infrastructure is focused primarily on the acute care setting. The company uses strategic collaboration with other industry players. Theravance generates the majority of its revenue in the U.S. and Europe, followed by Asia. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021Theravance Biopharma Earnings Preview© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
NEW YORK, NY / ACCESSWIRE / February 23, 2021 / Theravance Biopharma, Inc. (NASDAQ:TBPH) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 5:00 PM Eastern Time.